Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers.

Published in: Clinical chemistry (2022)

Because of their advantages, it is likely that ctDNA measurements will enter clinical use in the future, where they will complement existing biomarkers and imaging in managing patients with cancer. Hopefully, these combined approaches will lead to a better outcome for patients.

Keyphrases

circulating tumor
cell free
circulating tumor cells
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
high resolution
peritoneal dialysis
current status
small molecule
patient reported outcomes
protein protein
patient reported